Screener
Denali Therapeutics Inc. DNLI Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -54.9%-15.2pp | -49.6%-14.4pp | -45.7%-8.3pp | -44.4%-9.4pp | -39.7%-7.1pp | |
| Return on invested capital | -67.9%-21.3pp | -64.8%-24.5pp | -56.8%-9.5pp | -50.8%-8.2pp | -46.6%-7.6pp | |
| Liquidity | ||||||
| Current ratio | 8.4×-1.9× | 9.3×-0.3× | 9.2×+0.7× | 9.8×-0.2× | 10.3×-2.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.46-25.6% | $4.96-24.3% | $5.87-21.5% | $5.37-31.0% | $5.99-27.1% | |
| Valuation | ||||||
| Market capitalization | $3.92B+88.3% | $3.04B+54.2% | $2.58B-12.1% | $2.12B-49.1% | $2.09B-36.8% | |
| Price / book | 4.7×+2.7× | 3.3×+1.5× | 2.5×+0.2× | 2.3×-0.9× | 2×-0.4× |
FAQ
- Where do Denali Therapeutics Inc.'s ratios come from?
- Every ratio is computed from Denali Therapeutics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
